Regeneron and Sanofi have started a clinical program evaluating Kevzara (sarilumab) in patients hospitalised with severe Covid-19 infection.
Kevzara is a fully-human monoclonal antibody (mAB) that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor.
IL-6 may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with Covid-19. This is supported by preliminary data from a single-arm study in China using another IL-6 receptor antibody.
This US-based trial will begin at medical centres in New York, one of the epicentres of the US Covid-19 outbreak. It will assess the safety and efficacy of adding Kevzara to usual supportive care, compared to supportive care plus placebo.
The multi-centre, double-blind, Phase 2/3 trial has an adaptive design with two parts and is anticipated to enrol up to 400 patients.
The first part will recruit patients with severe Covid-19 infection across approximately 16 US sites and will evaluate the impact of Kevzara on fever and patients’ need for supplemental oxygen.
The second, larger part of the trial will evaluate the improvement in longer-term outcomes including preventing death and reducing the need for mechanical ventilation, supplemental oxygen and/or hospitalisation.
Building on past research
“To initiate this trial quickly, so that the results may inform evidence-based treatment of this ongoing pandemic, Regeneron and Sanofi have worked closely with the US Food and Drug Administration and the Biomedical Advanced Research and Development Authority, also known as the FDA and BARDA,” said George D. Yancopoulos, co-founder, President and Chief Scientific Officer of Regeneron.
“Data from China suggest that the IL-6 pathway may play an important role in the overactive inflammatory response in the lungs of patients with Covid-19. Despite this encouraging finding, it’s imperative to conduct a properly designed, randomized trial to understand the true impact.
“Our trial is the first controlled trial in the US to evaluate the effect of IL-6 inhibition prospectively in Covid-19 patients.
“In addition to our Kevzara program, Regeneron is also rapidly advancing a novel antibody cocktail for the prevention and treatment of Covid-19, which we hope to have available for human testing this summer.”
John Reed, Sanofi’s Global Head of R&D, said: “Scientific evidence has emerged to suggest that Kevzara may be a potentially important treatment option for critically-ill Covid-19 patients, and this trial will provide the well-controlled, rigorous scientific data we need to determine if IL-6 receptor inhibition with Kevzara is better than current supportive care alone.
“Additionally, we expect to rapidly initiate trials outside the US in the coming weeks, including areas most affected by the pandemic such as Italy,”. “In addition to Kevzara, Sanofi Pasteur, the vaccines global business unit of Sanofi, is leveraging previous development work for a SARS vaccine as part of our goal to quickly develop a Covid-19 vaccine.”
In late 2019, Regeneron and Sanofi announced their intent to simplify the joint collaboration for Kevzara, which is expected to be finalized in the first quarter of 2020.
The companies will continue to collaborate on Covid-19 and other related ARDS development, with Regeneron leading U.S.-based work and Sanofi leading work outside of the US.
The use of Kevzara to treat the symptoms of Covid-19 is investigational and has not been fully evaluated by any regulatory authority.